Apellis Pharma

Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which develops novel therapeutic and complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Apellis Pharma reports strong Q1 revenue, eyes U.S. expansion

Apellis Pharma's Q1 2023 performance showcased strong revenue from SYFOVRE and EMPAVELI, with positive feedback and demand in the market.
While facing challenges like safety concerns and European commercialization, the company is focused on expanding market reach and driving awareness.
Opportunities lie in making SYFOVRE widely available, promoting patient education, and potential approval in Europe for further growth.

Apellis Pharma reports robust Q2 sales amidst safety event challenges

Apellis Pharma's Q2 performance highlighted strong sales, positive product efficacy, and proactive response to safety events
Despite challenges with rare safety events, the company's strengths in product credibility, manufacturing quality, and market acceptance shine through
Opportunities lie in enhancing physician education, exploring financing options, and leveraging positive efficacy evolution for market growth
Overall, Apellis Pharma's strategic measures position it well to navigate challenges, capitalize on opportunities, and maintain market confidence

Apellis Pharma reports mixed Q3 results, eyes European expansion

Apellis Pharma's Q3 performance showed strong revenue from key products but also highlighted the need for cost-saving measures. The company's focus on global expansion and product launches in Europe presents growth opportunities amidst market challenges.

Apellis Pharma reports strong Q4 earnings amidst market challenges

Apellis Pharma delivered strong financial results in Q4 2023, driven by the success of SYFOVRE and EMPAVELI in the U.S., while navigating challenges in the EU market and competitive landscape.
The company's strategic focus on patient access, market leadership, and R&D advancement positions it for continued growth and innovation in precision medicine, supported by robust engagement with medical communities.
Opportunities lie in expanding market share through bilateral treatments, advancing pipeline programs, and leveraging compliance and real-world data to strengthen Apellis Pharma's position as a leading provider of GA therapies.
Addressing challenges such as market competition, regulatory processes, and financial performance will be crucial for Apellis Pharma to sustain growth, optimize revenue, and drive profitability in the future.

Apellis Pharma reports robust Q1 performance and eyes expansion

Apellis Pharma (APLS) showcased strong financial performance and product success in Q1 2024, with plans for expansion and upcoming study data.
Despite challenges like a negative CHMP opinion and safety concerns, opportunities in education, expansion, and market penetration are on the horizon.
The company's commitment to shareholder value, financial stability, and milestone achievements sets a positive outlook for the future.

Apellis Pharma reports robust Q2 earnings, eyes market expansion

Apellis Pharma's Q2 performance reflects strong revenue growth and market leadership, supported by successful product sales and strategic initiatives.
While facing competition and challenges in market share retention, the company's focus on expansion and financial strength bode well for future growth.
Opportunities in new indications, market expansion, and pipeline development position Apellis Pharma for continued value creation for patients and shareholders.

Apellis Pharma reports robust Q3 performance amidst market challenges

Apellis Pharma's Q3 performance reflects strong demand for SYFOVRE and strategic initiatives to drive market share.
While facing challenges such as gross to net adjustments and market dynamics, the company remains optimistic about future growth opportunities.
By leveraging strengths in product efficacy and real-world data, Apellis Pharma aims to expand globally and enhance profitability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. Its products include EMPAVELI and SYFOVRE. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, and Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.

WALTHAM, Mass., Jan.  16, 2020  (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced that the company approved the grant of an equity award to a new employee with a grant date of January 13, 2020, as an equity inducement award outside of the company's 2017 Stock Incentive Plan and material to the employee’s acceptance of employment with the company. The equity award was approved on December 13, 2019, in accordance with Nasdaq Listing Rule 5635(c)(4).

Apellis Pharmaceuticals - Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apellis Pharmaceuticals Phase 3 Success, And Other News: The Good, Bad, And Ugly Of Biopharma

Apellis Pharmaceuticals: PEGASUS Trial Confirms Pegcetacoplan's Efficacy Over Soliris In PNH Patients

Apellis Pharmaceuticals' (APLS) experimental drug pegcetacoplan outperformed Alexion's blockbuster medicine, Soliris, in a phase III head-to-head study. Shares soar.

Apellis' (APLS) PNH Drug Betters Alexion's Soliris in Study

The company's lead drug candidate bested a competitor's therapy on a key endpoint in a phase 3 trial.

Here's Why Apellis Pharmaceuticals Stock Jumped as Much as 40.7% Today

Pegcetacoplan is the first drug to beat Soliris in improving hemoglobin levels in PNH patients.

Apellis' Lead Drug Tops Alexion's Blockbuster Soliris in a Pivotal Late-Stage Study

Shares of Apellis Pharmaceuticals rocketed Tuesday after the biotech company's experimental drug outperformed Alexion Pharmaceuticals' blockbuster, Soliris, in a head-to-head test.

This Biotech Just Topped Alexion's Biggest Moneymaker — And Rocketed

Shares of Apellis Pharmaceuticals Inc. jumped 54% in premarket trading on Tuesday after the biopharmaceutical company said its experimental treatment for a rare blood disease met the primary efficacy endpoint in a late-stage trial.

Apellis stock soars on positive data for potential Soliris competitor

Apellis Pharmaceuticals Inc. (NASDAQ: APLS) shares jumped on Tuesday after the firm announced positive results from its late-stage study in adults with paroxysmal nocturnal hemoglobinuria (PNH).

Why This PNH Study Could Set the Standard for Treatment

WALTHAM, Mass., Jan.  07, 2020  (GLOBE NEWSWIRE) --  Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced positive results from the Phase 3 PEGASUS study evaluating pegcetacoplan (APL-2) in adults with paroxysmal nocturnal hemoglobinuria (PNH). Top-line data show that pegcetacoplan met the study’s primary efficacy endpoint, demonstrating superiority to eculizumab with a statistically significant improvement in adjusted means of 3.8 g/dL of hemoglobin at week 16 (p

Apellis Reports Positive Top-line Results from Phase 3 Head-to-Head Study of Pegcetacoplan (APL-2) Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Investors need to pay close attention to Apellis Pharmaceuticals (APLS) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Apellis Pharmaceuticals (APLS) Stock?

It looks like Apellis could have another competitor.

Here's Why Apellis Pharmaceuticals Fell Today

CRESTWOOD, Ky. and WALTHAM Mass., Nov.  15, 2019  (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (Nasdaq: APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced that the Company approved the grant of an equity award to a new employee with a grant date of November 11, 2019 as an equity inducement award outside of the Company's 2017 Stock Incentive Plan and material to the employee’s acceptance of employment with the Company. The equity award was approved on September 20, 2019, in accordance with Nasdaq Listing Rule 5635(c)(4).

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).

APL-2 demonstrated positive preliminary results across key renal measures including a nearly 50% reduction in proteinuria APL-2 demonstrated positive preliminary results across key renal measures including a nearly 50% reduction in proteinuria

Apellis Presents First Data on APL-2 in C3 Glomerulopathy at ASN Kidney Week

Reata Pharmaceuticals

Retrophin

Keeping up with the news from major medical meetings has become a requirement for healthcare investors.

3 Companies to Watch At Kidney Week 2019

Company also provides an update on plans in nephrology

Apellis to Present Data on APL-2 in Complement 3 Glomerulopathy at  ASN Kidney Week 2019

CRESTWOOD, Ky. and WALTHAM Mass., Oct.  04, 2019  (GLOBE NEWSWIRE) --  Apellis Pharmaceuticals  Inc., (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, announced that, on June 19, July 5 and August 9, 2019, the Company approved the grant of equity awards to three new employees with grant dates of September 30, 2019 and October 1, 2019, as equity inducement awards outside of the Company's 2017 Stock Incentive Plan and material to the employees’ acceptance of employment with the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule  5635(c)(4).

Apellis Pharmaceuticals (APLS) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Apellis Pharmaceuticals (APLS) Catches Eye: Stock Jumps 5.2%

Medicines

Syndax Pharmaceuticals

Needless to say, the biotech world has had a difficult 2019, with the SPDR S&P Biotech ETF (NYSE: XBI) down 20% from highs posted in April.

Baird Has 3 Top Biotech Picks With Huge Upcoming Potential Catalysts

CRESTWOOD, Ky. and WALTHAM, Mass., Sept.  26, 2019  (GLOBE NEWSWIRE) --  Apellis Pharmaceuticals  Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced that it will present at the 2019 Cantor Global Healthcare Conference on Thursday, October 3, 2019 at 11:15 a.m. ET in New York, NY.

Apellis Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference

CRESTWOOD, Ky., and WALTHAM Mass., Sept.  18, 2019  (GLOBE NEWSWIRE) --  Apellis Pharmaceuticals  Inc., (NASDAQ:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced details about its Phase 2 FILLY study investigating intravitreal (IVT) APL-2 (pegcetacoplan) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) have been published in   Ophthalmology   , the journal of the American Academy of Ophthalmology. Publication of the full study report follows the release of topline study results earlier this year and shows that treatment with APL-2 resulted in statistically significant reductions in the growth of GA lesion area compared to sham at month 12.

Phase 2 Study Published in Ophthalmology Highlights Efficacy and Safety Data of Intravitreal APL-2 for Geographic Atrophy Secondary to Age-Related Macular Degeneration

CRESTWOOD, Ky. and WALTHAM, Mass., Sept.  16, 2019  (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced the closing of its offering of $220.0 million aggregate principal amount of 3.500% convertible senior notes due 2026 (the “notes”). The notes were sold in a private offering to qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Apellis also granted to the initial purchasers of the notes a 13-day option to purchase up to an additional $33.0 million aggregate principal amount of the notes, solely to cover over-allotments, if any.

Apellis Pharmaceuticals Announces Closing of Offering of Convertible Senior Notes

The company is issuing convertible debt to pad its balance sheet and fund late-stage clinical trials.

Here's Why Apellis Pharmaceuticals Is Tumbling Today

CRESTWOOD, Ky., and WALTHAM, Mass., Sept.  12, 2019  (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced the pricing of its offering of $220.0 million aggregate principal amount of 3.500% convertible senior notes due 2026 (the “notes”). The notes will be sold in a private offering to qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Apellis also granted to the initial purchasers of the notes a 13-day option to purchase up to an additional $33.0 million aggregate principal amount of the notes, solely to cover over-allotments, if any. The offering is expected to close on September 16, 2019, subject to satisfaction of customary closing conditions.

Apellis Pharmaceuticals Announces Pricing of Offering of Convertible Senior Notes

CRESTWOOD, Ky., and WALTHAM, Mass., Sept.  11, 2019  (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced that it intends to offer, subject to market and other conditions, $200 million aggregate principal amount of convertible senior notes due 2026 (the “notes”) in a private offering to qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Apellis also expects to grant to the initial purchasers of the notes a 13-day option to purchase up to an additional $30 million aggregate principal amount of the notes, solely to cover over-allotments, if any. The offering is subject to market and other conditions, and there can be no assurance as to whether, when or on what terms the offering may be completed.

News for Apellis Pharma Stock (APLS)